Applied Health Economics and Health Policy

2008 - 2025

Current editor(s): Timothy Wrightson

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 8, issue 6, 2010

The missing technology pp. 361-371

Bianca Frogner

Catastrophic healthcare payments and impoverishment in the occupied Palestinian territory pp. 393-405

Awad Mataria, Firas Raad, Mohammad Abu-Zaineh and Cam Donaldson

Volume 8, issue 5, 2010

Burden and cost of hospital admissions for vaccine-preventable paediatric pneumococcal disease and non-typable Haemophilus influenzae otitis media in New Zealand pp. 281-300

Richard Milne and Stephen Hoorn

Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007 pp. 301-315

Javier Orofino, Javier Soto, Miguel Casado and Itziar Oyagüez

Cost of illness and drivers of cost in atrial fibrillation in Sweden and Germany pp. 317-325

Linus Jönsson, Åsa Eliasson, John Kindblom, Olle Almgren and Nils Edvardsson

Cost effectiveness of long-acting risperidone in Sweden pp. 327-341

Marja Hensen, Bart Heeg, Mickael Löthgren and Ben Hout

Issues surrounding orphan disease and orphan drug policies in Europe pp. 343-350

Alain Denis, Lut Mergaert, Christel Fostier, Irina Cleemput and Steven Simoens

Economic efficiency of alcohol policy pp. 351-354

Christopher Doran and Thameemul Jainullabudeen

Volume 8, issue 4, 2010

Oncologist preferences for health states associated with the treatment of advanced ovarian cancer pp. 217-223

Lisa Hess, Daniel Malone, Grant Skrepnek, Pamela Reed, Edward Armstrong and Stephen Coons

The effect of protest zeros on estimates of willingness to pay in healthcare contingent valuation analysis pp. 225-237

William Fonta, H. Ichoku and Jane Kabubo-Mariara

Audit of Diabetes-Dependent Quality of Life (ADDQoL) [Chinese version for Singapore] questionnaire pp. 239-249

Swee Soon, Su Goh, Yong Bee, Jiat Poon, Shu Li, Julian Thumboo and Hwee Wee

Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden pp. 251-265

J. Logman, Bart Heeg, Johan Herlitz and Ben Hout

Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada pp. 267-280

Sandra Tunis, Luc Sauriol and Michael Minshall

Volume 8, issue 3, 2010

Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60–69 years pp. 141-154

David Lee, Dominic Muston, Alison Sweet, Chris Cunningham, Andrew Slater and Kevin Lock

Public option and private profits pp. 155-165

Fabio Milani

Healthcare costs of atypical antipsychotic use for patients with bipolar disorder in a medicaid programme pp. 167-177

Ying Qiu, Alex Fu, Gordon Liu and Dale Christensen

Productivity loss resulting from coronary heart disease in Australia pp. 179-189

Henry Zheng, Fred Ehrlich and Janaki Amin

Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany pp. 191-202

Thilo Schaufler and Malte Wolff

A systematic data review of the cost of rehydration therapy pp. 203-214

Jay Pershad

Gary Buurman, 1944–2010 pp. 215-216

Stuart Birks

Volume 8, issue 2, 2010

Do reduced inpatient costs associated with highly active antiretroviral therapy (HAART) balance the overall cost for HIV treatment? pp. 75-88

Paul Farnham

Health system choice pp. 89-97

Paul Scuffham, Jennifer Whitty, Matthew Taylor and Ruth Saxby

Willingness to pay for maternal health outcomes pp. 99-109

Laura Ternent, Paul McNamee, David Newlands, Danielle Belemsaga, Adjima Gbangou and Suzanne Cross

Outpatient medication costs of patients with cystic fibrosis in Germany pp. 111-118

Daniela Eidt-Koch, Thomas Wagner, Thomas Mittendorf and J.-Matthias Schulenburg

Organization and estimated patient-borne costs of oral anticoagulation therapy in Italy pp. 119-128

Lorenzo Pradelli, Sergio Iannazzo, Orietta Zaniolo and Paola Botrugno

Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder pp. 129-140

Regina Rendas-Baum, Min Yang, Joseph Gricar and Gene Wallenstein

Volume 7, issue 4, 2009

Which barriers prevent the efficient use of resources in medical device sectors? pp. 209-217

Steven Simoens

Assessing comparative effectiveness research in the US pp. 219-224

Joshua Cohen and John Bridges

Cost effectiveness of antiretrovirals — long term or short term? pp. 225-227

Steffen Flessa

The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda pp. 229-243

Elliot Marseille, James Kahn, Christian Pitter, Rebecca Bunnell, William Epalatai, Emmanuel Jawe, Willy Were and Jonathan Mermin

A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine pp. 245-254

Derek Misurski, Maureen Lage, Rosalind Fabunmi and Kristina Boye

Cost savings associated with filling a 3-month supply of prescription medicines pp. 255-264

Atonu Rabbani and G. Alexander

Demand for outpatient healthcare pp. 265-277

Sisira Sarma

Volume 7, issue 3, 2009

Soft regulations in pharmaceutical policy making pp. 137-147

Björn Wettermark, Brian Godman, Bengt Jacobsson and Flora Haaijer-Ruskamp

Value-based insurance design in medicare pp. 149-154

William Encinosa

Financial risk of the Biotech Industry versus the Pharmaceutical Industry pp. 155-165

Joseph Golec and John Vernon

Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in Sweden pp. 167-180

Ivar Kristiansen, Kerstin Bingefors, Dag Nyholm and Dag Isacson

Economic evaluation of Sinfrontal®in the treatment of acute maxillary sinusitis in adults pp. 181-191

Kyra Kneis and Afschin Gandjour

The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK pp. 193-205

Zhimei Liu, Quan Doan, Jennifer Malin and Robert Leonar

Volume 7, issue 2, 2009

Implementing differential pricing for essential medicines via country-specific bilateral negotiated discounts pp. 71-89

Ebenezer Tetteh

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis pp. 91-108

Stephanie Earnshaw, Jonathan Graham, MerriKay Oleen-Burkey, Jane Castelli-Haley and Kenneth Johnson

Comparative utility of aripiprazole and haloperidol in schizophrenia pp. 109-119

John Kane, Edward Kim, Hong Kan, Zhenchao Guo, John Bates, Richard Whitehead and Andrei Pikalov

Aversion to geographic inequality and geographic variation in preferences in the context of healthcare pp. 121-136

Carlota Quintal

Volume 7, issue 1, 2009

Informing disinvestment through cost-effectiveness modelling pp. 1-9

Jonathan Karnon, Jill Carlton, Carolyn Czoski-Murray and Kevin Smith

Health-promoting schools pp. 11-17

Albert Lee

Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction pp. 19-29

Florence Canoui-Poitrine, Grégoire Jeanblanc, Corinne Alberti, Priscilla Armoogum, Ana Cebrian, Didier Carrié, Patrick Henry, Emmanuel Teiger, Michel Slama, Christian Spaulding and Isabelle Durand-Zaleski

Direct economic burden of high-risk and metastatic melanoma in the elderly pp. 31-41

Keith Davis, Debanjali Mitra, Srividya Kotapati, Ramy Ibrahim and Jedd Wolchok

Oral therapies for the treatment of pulmonary arterial hypertension pp. 43-59

George Dranitsaris and Sanjay Mehta

Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction pp. 61-70

Alan White, Howard Birnbaum, Dov Rothman and Nathaniel Katz

Volume 6, issue 4, 2008

Does extending health insurance coverage to the uninsured improve population health outcomes? pp. 217-230

James Thornton and Jennifer Rice

Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B pp. 231-246

Elizabeth Arnold, Yong Yuan, Uchenna Iloeje and Greg Cook

Volume 6, issue 2, 2008

The impact of banning smoking in workplaces pp. 81-92

Shane Allwright

The impact of direct-to-consumer advertised drugs on drug sales in the US and New Zealand pp. 93-102

Edward Norey, Tessa Simone and Shaker Mousa

Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting pp. 103-112

Elise Pelletier, Paula Smith, Kristina Boye, Derek Misurski, Sandra Tunis and Michael Minshall

Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women pp. 113-135

Dirk Mueller and Afschin Gandjour

Households’ willingness to pay for a motorcycle helmet in Hanoi, Vietnam pp. 137-144

Khanh Pham, Quynh Thi, Dennis Petrie, Jon Adams and Christopher Doran

The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care pp. 145-155

Edward Gardner, Moises Maravi, Cornelis Rietmeijer, Arthur Davidson and William Burman

Cost analysis of amlodipine versus enalapril in patients with coronary artery disease and normal blood pressure pp. 157-162

Joseph Menzin, Luke Boulanger, Simon Tang, Kamlesh Thakker and Steven Nissen